Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M.

Cancer Discov. 2012 Aug;2(8):685-93.

2.

RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.

Hanrahan AJ, Solit DB.

Cancer Discov. 2012 Aug;2(8):666-9. doi: 10.1158/2159-8290.CD-12-0308.

3.

KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.

Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC.

Mol Cancer Res. 2012 Sep;10(9):1228-39.

4.

Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.

Gysin S, Paquette J, McMahon M.

Mol Cancer Res. 2012 Dec;10(12):1607-19. doi: 10.1158/1541-7786.MCR-12-0188. Erratum in: Mol Cancer Res. 2013 Jun;11(6):686.

5.

Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.

Ji Z, Mei FC, Xie J, Cheng X.

J Biol Chem. 2007 May 11;282(19):14048-55.

6.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
7.

Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.

Shi G, DiRenzo D, Qu C, Barney D, Miley D, Konieczny SF.

Oncogene. 2013 Apr 11;32(15):1950-8. doi: 10.1038/onc.2012.210.

8.
9.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.

Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

10.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563.

11.

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma.

Luan Z, He Y, Alattar M, Chen Z, He F.

Mol Cancer. 2014 Feb 25;13:38. doi: 10.1186/1476-4598-13-38.

12.

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N.

Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409.

13.

K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways.

Matsuo Y, Campbell PM, Brekken RA, Sung B, Ouellette MM, Fleming JB, Aggarwal BB, Der CJ, Guha S.

Mol Cancer Res. 2009 Jun;7(6):799-808. doi: 10.1158/1541-7786.MCR-08-0577.

14.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Review.

15.

Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.

Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD, Yang GY.

Cancer Lett. 2016 Feb 28;371(2):187-93. doi: 10.1016/j.canlet.2015.11.042.

16.

ERK inhibition overcomes acquired resistance to MEK inhibitors.

Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.

Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010.

17.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011.

18.

MEK and RAF inhibitors for BRAF-mutated cancers.

Belden S, Flaherty KT.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Review.

PMID:
23058743
19.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513.

20.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683.

Supplemental Content

Support Center